Ciprofloxacin use and susceptibility of Gram-negative organisms to quinolone and non-quinolone antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2152-2158

  Troughton, Judith A ^a,b   Millar, Gary ^a   Smyth, Edward T M ^a   Doherty, Lorraine ^b,c   Mcmullan, Ronan ^a,b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c PUBLIC HEALTH AGENCY   (United Kingdom)

Author keywords

lactam susceptibility; Aminoglycoside susceptibility; Antimicrobial use; Gram negative susceptibility; Resistance surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS; BACTERIUM ISOLATE; BLOOD CULTURE; DRUG USE; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS; HUMAN; KLEBSIELLA; NONHUMAN; PROTEUS; PSEUDOMONAS; SERRATIA; SPUTUM CULTURE; URINE CULTURE;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG UTILIZATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 80051676169     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr264     Document Type: Article

References (38)

1. Chiew YF, Yeo SF, Hall LM et al. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J Antimicrob Chemother 1998; 41: 247-51.
2. Davey P, Brown E, Fenelon L et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; issue 4: CD003543.
3. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033-48.
4. McGowan JE Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med 1987; 63: 253-68.
5. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989; 23: 441-51.
6. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992; 17: 303-5.
7. Moller JK. Antimicrobial usage and microbial resistance in a university hospital during a seven-year period. J Antimicrob Chemother 1989; 24: 983-92.
8. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15: 37S-42S.
9. Coronado VG, Edwards JR, Culver DH et al. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16: 71-5.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
11. HPA. Laboratory Detection and Reporting of Bacteria with Extended Spectrum b-Lactamases. National Standard Method, QSOP51, 2008. http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop51. pdf (27 March 2011, date last accessed).
12. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2009. http://www.whocc.no/atc_ddd_index/ (9 November 2009, date last accessed).
13. Shlaes DM, Gerding DN, John JF Jr et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99.
14. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-86.
15. Siegal JD, Rhinehart E, Jackson M et al. Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006. http://www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf (13 March 2010, date last accessed).
16. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-40.
17. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8.
18. Goettsch W, van Pelt W, Nagelkerke N et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46: 223-8.
19. Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991- 2000. Clin Infect Dis 2003; 37: 1643-8.
20. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15: 478-83.
21. Patterson JE, Hardin TC, Kelly CA et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-8.
22. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-7.
23. Reuter S, Kern WV, Sigge A et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40: 1087-93.
24. Gottesman BS, Carmeli Y, Shitrit P et al. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009; 49: 869-75.
25. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol 2001; 9: 438-44.
26. Bergman M, Nyberg ST, Huovinen P et al. Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother 2009; 53: 912-7.
27. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-40.
28. Poirel L, Villa L, Bertini A et al. Expanded-spectrum b-lactamase and plasmid-mediated quinolone resistance. Emerg Infect Dis 2007; 13: 803-5.
29. Poirel L, Pitout JD, Calvo L et al. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum β-lactamase. Antimicrob Agents Chemother 2006; 50: 1525-7.
30. Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-8.
31. Cordeiro NF, Robino L, Medina J et al. Ciprofloxacin-resistant enterobacteria harboring the aac(6′)-Ib-cr variant isolated from feces of inpatients in an intensive care unit in Uruguay. Antimicrob Agents Chemother 2008; 52: 806-7.
32. Machado E, Coque TM, Canton R et al. Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6′)-Ib-cr gene, which encodes an aminoglycoside-and fluoroquinolone-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 3220-1.
33. Kim ES, Jeong JY, Jun JB et al. Prevalence of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. Antimicrob Agents Chemother 2009; 53: 2643-5.
34. Park CH, Robicsek A, Jacoby GA et al. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 3953-5.
35. Perichon B, Bogaerts P, Lambert T et al. Sequence of conjugative plasmid pIP1206 mediating resistance to aminoglycosides by 16S rRNA methylation and to hydrophilic fluoroquinolones by efflux. Antimicrob Agents Chemother 2008; 52: 2581-92.
36. Liu JH, Deng YT, Zeng ZL et al. Coprevalence of plasmid-mediated quinolone resistance determinants QepA, Qnr, and AAC(6′)-Ib-cr among 16S rRNA methylase RmtB-producing Escherichia coli isolates from pigs. Antimicrob Agents Chemother 2008; 52: 2992-3.
37. Davey P, Ferech M, Ansari F et al. Outpatient antibiotic use in the four administrations of the UK: cross-sectional and longitudinal analysis. J Antimicrob Chemother 2008; 62: 1441-7.
38. HPA Centre for Infections. Antimicrobial Resistance and Prescribing in England, Wales and Northern Ireland, 2008. http://www.hpa.org.uk/ Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfec tions/0807Antimicrobialresistance2008/ (13 September 2010, date last accessed).